Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,146 public trials 2,034 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

NCT06517511

Conditions: Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Sun yat-sen university cancer center Guangzhou, Guangdong, China

Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

National Longitudinal Cohort of Hematological Diseases

NCT04645199

Conditions: Acute Myeloid Leukemia, Anemia, Anemia, Aplastic, +53 more
Locations: Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT06644183

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +18 more
Locations: Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

NCT07206121

Conditions: Breast Cancer, Breast Cancer - Infiltrating Ductal Carcinoma, Breast Diseases, +17 more
Locations: University of Texas Medical Branch at Galveston, TX Galveston, Texas, United States

View Trial Details

Recruiting

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

NCT07018752

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Institut d'Hématologie de Basse Normandie - Service Hématologie (CHU Hôpital Côte de Nacre) Caen, France

CHU Estaing - Service Thérapie Cellulaire et Hématologie Clinique Clermont-Ferrand, France

Hôpital Henri Mondor - Unité Hémopathies Lymphoïdes Créteil, France

CHU Dijon Bourgogne - Service Hématologie Clinique Dijon, France

View all 20 locations

View Trial Details

Recruiting

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

NCT05992532

Conditions: Acid Sphingomyelinase Deficiency, Blood Protein Disorders, Brain Diseases, +38 more
Locations: Hospital Universitario de Álava Vitoria-Gasteiz, Alava, Spain

Hospital Universitario Torrecárdenas Almería, Spain

Hospital Son Espases Palma de Mallorca, Balearic Islands, Spain

Hospital Parc Taulí Sabadell, Barcelona, Spain

View all 23 locations

View Trial Details

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

NCT06287528

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Suffolk-Commack (Limited Protocol Activities) Commack, New York, United States

View Trial Details

Recruiting

A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

NCT06860269

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Hôpital Saint Louis Paris, France

View Trial Details

Recruiting

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

NCT05592015

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Dana-Farber Cancer Institute Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center New York, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

NCT04848064

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions